Prediction Case File
YouTubeTracking Live

Friends! In this video, I'm going to talk about the best 2 stocks to consider

2 extracted signals · 0 resolved · 2 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
07 Nov 2025, 00:26 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, I'm going to talk about the best  2 stocks to consider
Source overview

AI-generated source summary

The analyst reviews two stocks for November. META trades at 21 times forward earnings and with access to 3.5 billion daily active people. Revenue growth is reaccelerating from 16% to 26%. Meta has the potential for higher earnings per share. A significant capital expenditure is leading to Meta's Metaverse moment. The presenter stated that if the capital expenditure takes too long to produce results, the core business is still solid. The presenter estimates a failure bound of $500 and a target of $980. The analyst then covers Cheniere Energy (LNG), an uncorrelated natural gas stock. LNG is down 12% over the last month. The analyst states that Cheniere Energy has the second largest liquefaction facility in the US, providing natural gas to Europe and Asia. LNG's most recent earnings are impressive. The LNG global capacity should increase by 60% by the end of the decade. However, demand is not going to match capacity. The current price is around $205 and their analysis indicates the stock has around $25 DE around 2030 with a price target of $400.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Tracking Live
Signals
2
Extracted from this source
Open
2
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
—
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    2 eligible signals linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. Live evaluation in progress

    2 signals remain active.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.5
Tracked signals
359
Historical success
34.3%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail